Details of the Drug

General Information of Drug (ID: DMM0XGL)

Drug Name
Idarubicin
Synonyms
DMDR; Idamycin; Idarubicina; Idarubicine; Idarubicinum; Zavedos; Idarubicin Hcl; Idarubicin Hcl Pfs; Idarubicin hydrochloride; DM5; I 1656; IMI 30; IMI-30; Idamycin (TN); Idarubicin (INN); Idarubicin [INN:BAN]; Idarubicina [INN-Spanish]; Idarubicine [INN-French]; Idarubicinum [INN-Latin]; Zavedos (TN); (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (1s,3s)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-A-l-lyxo-hexopyranoside; (7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S-cis)-9-Acetyl-7-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,9,11-trihydroxy-5,12-naphthacenedione; 4-DMD; 4-Demethoxydaunomycin; 4-Demethoxydaunorubicin; 4-Desmethoxydaunorubicin
Indication
Disease Entry ICD 11 Status REF
Acute myelogenous leukaemia 2A41 Approved [1]
Acute myeloid leukaemia 2A60 Approved [2]
Adult acute monocytic leukemia N.A. Approved [1]
Childhood acute megakaryoblastic leukemia N.A. Approved [1]
Leukemia N.A. Approved [1]
Therapeutic Class
Anticancer Agents
Affected Organisms
Humans and other mammalsBacteria
ATC Code
L01DB06: Idarubicin
L01DB: Anthracyclines and related substances
L01D: CYTOTOXIC ANTIBIOTICS AND RELATED SUBSTANCES
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 497.5
Logarithm of the Partition Coefficient (xlogp) 1.9
Rotatable Bond Count (rotbonds) 3
Hydrogen Bond Donor Count (hbonddonor) 5
Hydrogen Bond Acceptor Count (hbondacc) 10
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 24 mL/min/kg [4]
Elimination
3% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 22 hours [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 5.42707 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.076% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 38 L/kg [4]
Chemical Identifiers
Formula
C26H27NO9
IUPAC Name
(7S,9S)-9-acetyl-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-8,10-dihydro-7H-tetracene-5,12-dione
Canonical SMILES
C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O
InChI
InChI=1S/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3/t10-,15-,16-,17-,21+,26-/m0/s1
InChIKey
XDXDZDZNSLXDNA-TZNDIEGXSA-N
Cross-matching ID
PubChem CID
42890
ChEBI ID
CHEBI:42068
CAS Number
58957-92-9
UNII
ZRP63D75JW
DrugBank ID
DB01177
TTD ID
D01XDL
VARIDT ID
DR00386
INTEDE ID
DR0852
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN ; TOP2B_HUMAN Modulator [6]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [7]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [8]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [8]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [9]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [9]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Gene/Protein Processing [10]
Bile acid receptor (NR1H4) OTWZLPTB NR1H4_HUMAN Gene/Protein Processing [10]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Gene/Protein Processing [11]
Estrogen receptor (ESR1) OTKLU61J ESR1_HUMAN Gene/Protein Processing [10]
Heme oxygenase 1 (HMOX1) OTC1W6UX HMOX1_HUMAN Gene/Protein Processing [12]
Natriuretic peptides B (NPPB) OTSN2IPY ANFB_HUMAN Gene/Protein Processing [13]
Peroxisome proliferator-activated receptor delta (PPARD) OTI4WTOP PPARD_HUMAN Gene/Protein Processing [10]
Peroxisome proliferator-activated receptor gamma (PPARG) OTHMARHO PPARG_HUMAN Gene/Protein Processing [10]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Gene/Protein Processing [14]
Vitamin D3 receptor OTFC7K35 VDR_HUMAN Gene/Protein Processing [10]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U2OS CTRP1 -1.4407 1.4923 -3.2624 9.8945
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MCF-7 CTRP1 -1.6858 2.6628 -4.0355 17.1037
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
GaMG CTRP1 -3.3268 1.4042 -3.4127 60.5949
SF295 CTRP1 -3.1476 5.013 -3.8846 76.6679
LN-229 CTRP1 -2.5697 1.4991 -4.211 22.3537
Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHUEM-2 CTRP1 -8.4963 -5.7991 -8.508 84.4457
HEC-151 CTRP1 -6.7566 0.5198 -8.0269 58.993
KLE CTRP1 -4.911 0.4473 -4.9915 69.9206
MFE-319 CTRP1 -3.4311 0.2127 -3.4509 92.0469
HEC-265 CTRP1 -3.065 -1.8459 -3.065 99.0171
HEC-6 CTRP1 -2.3858 -0.6161 -2.386 94.767
HEC-251 CTRP1 -2.0778 0.1799 -2.0798 90.7807
HEC-108 CTRP1 -1.6528 0.8086 -1.6584 49.3188
HEC-59 CTRP1 -1.2262 0.22 -1.2263 46.1813
Ishikawa (Heraklio) 02 ER- CTRP1 -3.4758 -1.9851 -3.4758 62.7082
⏷ Show the Full List of 10 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 24 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NU-DUL-1 CTRP1 -9.3343 -6.6979 -9.3394 90.7208
SU-DHL-5 CTRP1 -8.5042 -7.6395 -8.5042 92.1327
SKM-1 CTRP1 -6.3606 -4.6293 -6.3663 62.7273
OCI-AML-3 CTRP1 -6.1275 -4.5953 -6.131 59.6239
NOMO-1 CTRP1 -5.6086 -3.4685 -5.6528 52.2335
KMS-11 CTRP1 -5.512 -0.2026 -6.4211 50.6071
WSU-DLCL2 CTRP1 -5.3475 -3.556 -5.3721 48.6665
THP-1 CTRP1 -5.3366 -3.3398 -5.379 48.5375
GDM-1 CTRP1 -4.5433 -1.6946 -4.8524 38.8691
U-937 CTRP1 -4.3552 -2.8179 -4.3984 34.7535
PL21 CTRP1 -4.2903 -1.7317 -4.5655 35.3051
KE-97 CTRP1 -4.0358 -2.6651 -4.0358 99.6948
Ku812 CTRP1 -4.0248 -1.7045 -4.0251 98.0385
P3HR-1 CTRP1 -3.9387 -1.2976 -3.94 97.0248
BL-70 CTRP1 -3.9132 -1.9389 -3.9133 65.8873
AMO1 CTRP1 -3.3925 2.2914 -5.3633 33.3086
SU-DHL-4 CTRP1 -3.3862 -1.7607 -3.5714 22.0107
MOLM-16 CTRP1 -3.1563 -1.6077 -3.3718 18.9809
MC116 CTRP1 -2.8398 -1.3412 -2.8399 97.6873
OCI-Ly10 CTRP1 -2.7364 -1.0616 -3.1439 14.6202
HT CTRP1 -2.6939 -0.6915 -2.6943 95.2735
RPMI-8226 CTRP1 -2.5822 0.1995 -3.5847 17.5502
EJM CTRP1 -2.2369 -1.4782 -2.4502 5.9474
LP-1 CTRP1 -0.6735 2.3878 -3.1643 6.6719
⏷ Show the Full List of 24 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
VMRC-RCW CTRP1 -4.07 5.1476 -4.9282 78.1982
RCC10RGB CTRP1 -1.0482 1.3469 -2.9157 5.6659
Cancer Drug Sensitivity Data Curated from 37 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-175 CTRP1 -7.5341 -3.9225 -7.6402 72.3327
SNU-C4 CTRP1 -5.356 1.839 -7.104 49.3901
LS180 CTRP1 -5.1452 11.879 -11.6757 49.0538
CL-34 CTRP1 -5.0815 -2.3227 -5.2725 45.4363
KM12 CTRP1 -4.5237 -1.0514 -5.045 39.5538
SNU-81 CTRP1 -4.3024 -0.335 -5.0839 37.9799
SW948 CTRP1 -4.0454 1.0706 -5.4281 37.5206
SW48 CTRP1 -4.018 -1.5873 -4.0186 97.7537
SNU-C5 CTRP1 -4.0159 -0.658 -4.6511 33.761
LoVo CTRP1 -3.5671 -0.3974 -4.2886 28.4972
HT115 CTRP1 -3.4152 0.6385 -4.6 29.5394
GP2d CTRP1 -3.3149 -1.1607 -3.3153 96.9179
SK-CO-1 CTRP1 -3.1323 1.5012 -3.2173 87.0526
LS513 CTRP1 -2.6827 -0.117 -2.6858 92.9273
RKO CTRP1 -2.6129 0.0139 -3.5238 17.1957
CL-40 CTRP1 -2.5857 2.0868 -4.5159 24.4989
DLD-1 CTRP1 -2.5267 2.8576 -2.739 81.2159
CW-2 CTRP1 -2.4859 2.7943 -4.7783 25.6286
HCT 116 CTRP1 -2.4474 0.3094 -3.5132 16.2819
LS411N CTRP1 -2.4014 3.9827 -2.8161 77.4531
NCI-H508 CTRP1 -2.3739 0.2909 -3.4369 15.2791
COLO205 CTRP1 -2.3482 1.9908 -2.4389 83.8569
SNU-1040 CTRP1 -2.1557 -0.682 -2.7587 8.2768
SNU-61 CTRP1 -1.9678 -0.3567 -2.7572 7.4356
C2BBe1 CTRP1 -1.909 6.9404 -3.1312 69.2777
HT-55 CTRP1 -1.8727 -0.8704 -2.4222 4.0315
RCM-1 [Human ESC] CTRP1 -1.7909 0.7833 -3.1819 10.5102
COLO 678 CTRP1 -1.6913 0.7226 -3.0726 9.1594
SNU-C2A CTRP1 -1.6239 2.9896 -1.7912 78.0741
MDST8 CTRP1 -1.2353 2.3291 -3.5221 11.354
HCT 8 CTRP1 -1.086 0.9831 -2.7688 4.5459
COLO 320 CTRP1 -0.5606 2.4548 -4.0105 3.6607
SW403 CTRP1 -0.2857 3.2249 -0.3946 70.2075
SW620 CTRP1 0.0153 5.6111 -4.2395 12.79
LS123 CTRP1 0.059 2.619 -2.851 2.7376
HT-29 CTRP1 0.693 2.0146 -2.3641 0.1066
SW480 CTRP1 1.4206 6.983 -4.0129 7.8972
⏷ Show the Full List of 37 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 4 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SNU-398 CTRP1 -2.5919 -0.7467 -3.1415 13.8149
Hep-G2 CTRP1 -1.7677 0.151 -2.848 7.451
JHH-6 CTRP1 -1.1931 0.125 -1.1931 45.938
SNU-449 CTRP1 -0.9427 1.724 -0.9598 44.1444
Cancer Drug Sensitivity Data Curated from 91 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H1963 CTRP1 -5.5519 -1.3124 -6.0702 51.1152
NCI-H596 CTRP1 -5.2776 -2.1385 -5.5307 48.0079
LXF 289 CTRP1 -5.0544 -0.6349 -5.0806 72.0124
SCLC-21H CTRP1 -4.6994 -0.6905 -5.3668 42.1427
VMRC-LCD CTRP1 -4.4915 2.8266 -4.8501 84.4611
NCI-H2286 CTRP1 -4.4174 -1.3141 -4.4209 69.1006
A-549 CTRP1 -4.2734 2.3535 -4.5351 85.5589
HCC78 CTRP1 -4.187 0.0531 -4.2188 92.7344
NCI-H661 CTRP1 -4.0552 2.2023 -4.2783 85.7837
NCI-H2073 CTRP1 -4.0108 0.3605 -5.0752 35.8548
SK-LU-1 CTRP1 -3.9658 -0.9257 -4.4929 32.4784
NCI-H1048 CTRP1 -3.7378 -1.4727 -3.7382 97.6268
ChaGo-K-1 CTRP1 -3.7188 -1.2938 -3.7196 97.1334
NCI-H2009 CTRP1 -3.6483 1.5516 -3.7648 60.8913
NCI-H1930 CTRP1 -3.6477 -0.5919 -3.653 63.6969
NCI-H1299 CTRP1 -3.6173 -0.0372 -3.6331 92.9981
DMS 273 CTRP1 -3.4467 -0.5247 -3.4511 94.7224
KNS-62 CTRP1 -3.4198 -0.7604 -3.422 95.5482
NCI-H460 CTRP1 -3.4005 0.0145 -4.2994 27.5336
NCI-H1568 CTRP1 -3.3997 -0.0839 -3.4108 93.128
NCI-H2141 CTRP1 -3.3874 -0.7093 -3.9691 25.093
NCI-H82 CTRP1 -3.27 -1.675 -3.27 98.4574
COR-L279 CTRP1 -3.2416 -1.5744 -3.2416 98.2037
COLO 668 CTRP1 -3.2036 -2.1018 -3.2036 60.7103
LCLC-97TM1 CTRP1 -3.1725 0.1223 -3.1848 92.2766
NCI-H1793 CTRP1 -3.0382 4.0078 -3.5145 78.9424
NCI-H2029 CTRP1 -3.0375 -0.8618 -3.0381 95.9635
HCC15 CTRP1 -3.0282 0.2242 -4.0251 23.41
NCI-H1792 CTRP1 -3.0147 0.9741 -3.0568 88.8749
HCC33 CTRP1 -3.0049 0.8591 -3.0405 89.306
NCI-H810 CTRP1 -2.9907 1.2334 -3.0482 87.8621
NCI-H1105 CTRP1 -2.9812 -0.6321 -3.5842 19.6747
NCI-H2405 CTRP1 -2.9343 6.6603 -4.1489 72.7277
LC-1/sq-SF CTRP1 -2.8932 4.0372 -3.3634 78.5384
NCI-H522 CTRP1 -2.7698 -0.236 -2.7724 93.476
NCI-H23 CTRP1 -2.7222 0.8302 -2.7482 89.0874
HCC1833 CTRP1 -2.6801 -0.6359 -3.2802 15.4744
Lu-99 CTRP1 -2.6273 -0.5986 -2.6278 94.8697
Calu-6 CTRP1 -2.6136 6.4652 -3.7367 72.2572
NCI-H1876 CTRP1 -2.5618 -1.7038 -2.6961 9.8762
SHP-77 CTRP1 -2.5278 -0.5543 -2.5282 94.625
Lu-65 CTRP1 -2.5268 4.8126 -3.1536 75.61
HCC2108 CTRP1 -2.5008 1.8298 -4.3125 22.7268
NCI-H1694 CTRP1 -2.4199 -1.7595 -2.5231 7.607
NCI-H1944 CTRP1 -2.3856 3.4698 -2.6933 78.9144
NCI-H3255 CTRP1 -2.3777 0.5227 -3.5548 16.2977
NCI-H2122 CTRP1 -2.3635 1.4529 -4.0032 19.8257
COR-L88 CTRP1 -2.3351 14.9513 -6.8777 61.9416
HCC44 CTRP1 -2.3098 3.3822 -2.5949 78.9786
NCI-H1781 CTRP1 -2.299 3.4326 -4.9332 25.6474
NCI-H1573 CTRP1 -2.2403 1.7225 -2.3023 84.634
NCI-H2081 CTRP1 -2.1255 -0.6083 -2.7682 8.2229
EBC-1 CTRP1 -2.0911 3.7381 -2.4272 77.2611
NCI-H2126 CTRP1 -2.0725 0.1122 -2.074 91.0702
DV-90 CTRP1 -2.0538 0.8737 -2.0666 87.6836
NCI-H1666 CTRP1 -2.0522 1.2622 -2.0791 86.0323
NCI-H841 CTRP1 -2.0503 -0.3386 -2.8365 8.5016
HARA [Human squamous cell lung carcinoma] CTRP1 -2.049 -0.053 -2.0497 91.755
NCI-H650 CTRP1 -2.011 1.754 -2.0654 83.9165
NCI-H1373 CTRP1 -1.9928 0.4538 -1.9967 89.3646
HCC1359 CTRP1 -1.9556 -0.8546 -2.498 5.0488
NCI-H1435 CTRP1 -1.9478 0.2484 -1.9496 51.4801
LCLC-103H CTRP1 -1.9113 -0.6446 -1.9113 94.073
NCI-H358 CTRP1 -1.8978 -0.0225 -1.8983 91.2359
NCI-H1836 CTRP1 -1.8809 -0.2963 -2.7154 6.7034
COR-L23 CTRP1 -1.8456 0.0358 -2.8527 7.7967
HCC1195 CTRP1 -1.7777 -0.4075 -2.578 5.0696
Calu-3 CTRP1 -1.7576 5.1039 -2.3925 72.5109
EPLC-272H CTRP1 -1.7124 1.633 -1.7477 83.4794
NCI-H441 CTRP1 -1.7094 1.2216 -3.3354 11.5269
NCI-H1755 CTRP1 -1.7061 0.1989 -2.8237 7.0021
NCI-H2023 CTRP1 -1.6555 0.1866 -2.779 6.4187
NCI-H2030 CTRP1 -1.615 -0.0206 -2.6468 5.1026
HCC2935 CTRP1 -1.5976 0.8654 -3.0711 8.7966
NCI-H2342 CTRP1 -1.4868 2.744 -3.9183 15.4316
NCI-H1437 CTRP1 -1.233 1.486 -1.2482 82.0805
NCI-H727 CTRP1 -1.2205 2.7009 -1.3233 77.4067
COLO 699 CTRP1 -1.1592 0.5297 -2.6036 3.3801
CAL-12T CTRP1 -1.1014 0.9967 -2.7849 4.7223
T3M-10 CTRP1 -1.0345 1.094 -2.788 4.5662
NCI-H1975 CTRP1 -0.9883 3.3081 -1.1582 74.2482
NCI-H1915 CTRP1 -0.6538 1.7452 -0.6654 42.0121
RERF-LC-KJ CTRP1 -0.5354 2.0613 -0.556 41.1716
NCI-H2110 CTRP1 -0.5104 9.6347 -6.5859 26.4295
HCC4006 CTRP1 -0.4994 2.3619 -3.0449 5.2756
HCC827 CTRP1 -0.22 4.483 -3.8588 10.7838
NCI-H1355 CTRP1 -0.1908 5.291 -0.7353 64.7425
Sq-1 CTRP1 -0.1835 1.6164 -2.5577 1.2911
NCI-H2172 CTRP1 0.0158 2.8578 -2.9749 3.6544
BEN CTRP1 0.5225 5.4012 0.0107 59.6303
COR-L51 CTRP1 0.5645 18.3075 -10.0623 32.4527
⏷ Show the Full List of 91 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KYSE-450 CTRP1 -2.1294 0.0077 -2.1306 91.6548
KYSE-140 CTRP1 -1.6027 1.0971 -1.6136 85.3244
KYSE-410 CTRP1 -0.5435 3.1067 -0.6538 72.3243
Cancer Drug Sensitivity Data Curated from 26 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
OVCAR-8 CTRP1 -7.6649 2.065 -9.604 61.7163
OVKATE CTRP1 -5.8629 1.3597 -7.4223 52.9169
COV434 CTRP1 -5.4817 -2.0645 -5.7725 50.443
A2780 CTRP1 -5.4362 2.2613 -7.3725 49.9527
SK-OV-3 CTRP1 -4.9323 9.2705 -7.2277 72.7518
JHOC-5 CTRP1 -4.5694 -1.1446 -5.0613 39.9969
OVK18 CTRP1 -3.933 -1.1736 -4.3647 31.4414
TYK-nu CTRP1 -3.4986 -0.6781 -4.0983 26.7342
OVCAR-4 CTRP1 -3.1894 8.3502 -8.1622 39.7911
HEY A8 CTRP1 -3.1329 -0.605 -3.1348 95.0196
Caov-3 CTRP1 -2.6692 -1.6045 -2.8483 11.765
JHOS-4 CTRP1 -2.4944 1.6781 -2.5643 55.1955
IGROV-1 CTRP1 -2.4686 1.9158 -4.3264 22.666
OV7 CTRP1 -2.3319 -0.2468 -3.1338 12.4407
EFO-27 CTRP1 -2.0661 0.0781 -3.0581 10.5546
OV-90 CTRP1 -2.0006 0.3059 -3.1161 10.7887
RMUG-S CTRP1 -1.9338 1.624 -3.7192 15.6629
OAW42 CTRP1 -1.7909 -0.7017 -2.4422 3.9024
JHOM-1 CTRP1 -1.5218 3.286 -4.2156 17.7662
RMG-I CTRP1 -1.5126 3.9364 -4.5324 19.8853
COV362 CTRP1 -1.0829 4.4242 -4.4416 17.6743
SNU-840 CTRP1 0.2017 6.2841 -4.4361 13.5587
COV644 CTRP1 0.6206 2.4498 -2.5394 0.5345
COV318 CTRP1 0.8291 5.2326 0.3943 32.6274
OVMANA CTRP1 0.8806 3.4418 0.8177 30.9326
EFO-21 CTRP1 1.805 8.4095 0.2501 48.1558
⏷ Show the Full List of 26 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 10 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Capan-2 CTRP1 -4.7984 1.7131 -5.0041 87.8177
SUIT-2 CTRP1 -4.2244 3.4125 -4.6749 82.5816
QGP-1 CTRP1 -3.3416 3.8985 -3.82 79.8599
KP-3 CTRP1 -3.1247 2.8817 -3.3858 82.3851
HuP-T4 CTRP1 -2.9953 0.5597 -3.0174 90.4602
PaTu 8902 CTRP1 -2.1195 1.5059 -2.1615 52.6567
Panc 03.27 CTRP1 -1.955 1.2703 -1.9795 85.7369
CFPAC-1 CTRP1 -1.7184 2.3336 -1.8096 80.7577
Panc 10.05 CTRP1 -1.6072 4.7935 -2.1452 72.7197
HPAC CTRP1 -1.3207 -0.5578 -1.3207 90.3641
⏷ Show the Full List of 10 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MSTO-211H CTRP1 -4.3229 -1.9393 -4.3233 98.3668
NCI-H2052 CTRP1 -2.5844 2.1902 -2.7097 83.6446
NCI-H28 CTRP1 -0.4389 4.6136 -0.8256 67.6536
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
PaCa-3 CTRP1 -2.9635 0.8803 -2.9988 58.56
Cancer Drug Sensitivity Data Curated from 9 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-375 CTRP1 -5.256 -1.1462 -5.8038 48.0375
Hs 936.T CTRP1 -2.9651 0.1858 -2.9757 91.9098
Hs 944.T CTRP1 -2.9182 0.0943 -2.9263 92.2415
G-361 CTRP1 -2.8896 0.1221 -2.8979 92.1105
COLO 741 CTRP1 -2.7322 1.3425 -2.787 87.0815
Hs 852.T CTRP1 -2.1796 -0.2896 -2.18 53.1843
SK-MEL-5 CTRP1 -1.9165 -0.431 -2.6773 6.5041
SK-MEL-1 CTRP1 -1.0628 4.5371 -4.4822 17.8703
SK-MEL-28 CTRP1 0.1094 2.878 -2.9346 3.2092
⏷ Show the Full List of 9 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
G-401 CTRP1 -4.3513 -2.0315 -4.3516 98.5367
HT-1080 CTRP1 -2.0529 2.1147 -4.0644 18.8684
RKN CTRP1 -1.881 0.3932 -3.0601 9.7939
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
AGS CTRP1 -8.2395 -1.6179 -8.9061 69.8622
MKN7 CTRP1 -4.4749 14.6049 -8.9132 66.5056
SH-10-TC CTRP1 -2.7391 1.4483 -2.8017 86.6858
NUGC-4 CTRP1 -1.9938 0.7097 -2.0018 88.2431
Fu97 CTRP1 -1.3998 0.3094 -1.4002 87.7706
MKN74 CTRP1 -0.8815 1.3301 -0.887 43.665
SNG-M CTRP1 -2.0613 0.1003 -2.0627 52.3129
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HSC-2 CTRP1 -2.9175 -0.7196 -2.9182 95.4339
SCC-9 CTRP1 -1.7732 0.2842 -2.9187 8.1044
Cancer Drug Sensitivity Data Curated from 5 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HT-1376 CTRP1 -5.558 3.6907 -6.1848 83.4096
RT-4 CTRP1 -3.4825 -1.3438 -3.4828 97.4052
UM-UC-3 CTRP1 -3.4809 1.7576 -3.61 86.578
5637 CTRP1 -3.0811 -0.214 -3.0862 93.532
KMBC-2 CTRP1 -2.7909 2.6957 -2.9975 82.3343

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Idarubicin
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Idarubicin and Ivosidenib. Acute myeloid leukaemia [2A60] [15]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Midostaurin. Acute myeloid leukaemia [2A60] [16]
Arn-509 DMT81LZ Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Arn-509. Acute myeloid leukaemia [2A60] [17]
Gilteritinib DMTI0ZO Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Gilteritinib. Acute myeloid leukaemia [2A60] [18]
Coadministration of a Drug Treating the Disease Different from Idarubicin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sarecycline DMLZNIQ Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Sarecycline . Acne vulgaris [ED80] [19]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Oliceridine. Acute pain [MG31] [16]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Idarubicin and Ivabradine. Angina pectoris [BA40] [17]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Idarubicin and Bepridil. Angina pectoris [BA40] [16]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Idarubicin and Dronedarone. Angina pectoris [BA40] [16]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Idarubicin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [20]
Posaconazole DMUL5EW Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Posaconazole. Aspergillosis [1F20] [19]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Levalbuterol. Asthma [CA23] [21]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Idarubicin and Pirbuterol. Asthma [CA23] [22]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Idarubicin and Roflumilast. Asthma [CA23] [17]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [17]
Clarithromycin DM4M1SG Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Clarithromycin. Bacterial infection [1A00-1C4Z] [19]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Idarubicin and Sparfloxacin. Bacterial infection [1A00-1C4Z] [23]
ABT-492 DMJFD2I Minor Decreased absorption of Idarubicin due to intestinal mucosa variation caused by ABT-492. Bacterial infection [1A00-1C4Z] [24]
Retigabine DMGNYIH Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Retigabine. Behcet disease [4A62] [19]
Erdafitinib DMI782S Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [25]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Eribulin. Breast cancer [2C60-2C6Y] [16]
Lapatinib DM3BH1Y Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Lapatinib. Breast cancer [2C60-2C6Y] [19]
HKI-272 DM6QOVN Moderate Decreased clearance of Idarubicin due to the transporter inhibition by HKI-272. Breast cancer [2C60-2C6Y] [19]
Tucatinib DMBESUA Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Tucatinib. Breast cancer [2C60-2C6Y] [19]
Alpelisib DMEXMYK Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Alpelisib. Breast cancer [2C60-2C6Y] [19]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Idarubicin and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [26]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Olodaterol. Chronic obstructive pulmonary disease [CA22] [22]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Vilanterol. Chronic obstructive pulmonary disease [CA22] [21]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Idarubicin and Indacaterol. Chronic obstructive pulmonary disease [CA22] [22]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Arformoterol. Chronic obstructive pulmonary disease [CA22] [22]
Ulipristal DMBNI20 Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Ulipristal. Contraceptive management [QA21] [19]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Sevoflurane. Corneal disease [9A76-9A78] [16]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Probucol. Coronary atherosclerosis [BA80] [16]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Idarubicin and Pasireotide. Cushing syndrome [5A70] [16]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Osilodrostat. Cushing syndrome [5A70] [17]
Ivacaftor DMZC1HS Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Ivacaftor. Cystic fibrosis [CA25] [19]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Clomipramine. Depression [6A70-6A7Z] [16]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [16]
Deutetrabenazine DMUPFLI Moderate Additive CNS depression effects by the combination of Idarubicin and Deutetrabenazine. Dystonic disorder [8A02] [27]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Idarubicin and Ingrezza. Dystonic disorder [8A02] [28]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Solifenacin. Functional bladder disorder [GC50] [16]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Sunitinib. Gastrointestinal stromal tumour [2B5B] [16]
Boceprevir DMBSHMF Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Boceprevir. Hepatitis virus infection [1E50-1E51] [19]
Telaprevir DMMRV29 Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Telaprevir. Hepatitis virus infection [1E50-1E51] [19]
Daclatasvir DMSFK9V Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Daclatasvir. Hepatitis virus infection [1E50-1E51] [19]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [29]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Idarubicin and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [30]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [16]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Idarubicin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [31]
BMS-201038 DMQTAGO Moderate Decreased clearance of Idarubicin due to the transporter inhibition by BMS-201038. Hyper-lipoproteinaemia [5C80] [19]
Tolvaptan DMIWFRL Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [19]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Idarubicin and Polyethylene glycol. Irritable bowel syndrome [DD91] [17]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Idarubicin and Denosumab. Low bone mass disorder [FB83] [32]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Idarubicin and Crizotinib. Lung cancer [2C25] [33]
Brigatinib DM7W94S Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Brigatinib. Lung cancer [2C25] [19]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Idarubicin and Ceritinib. Lung cancer [2C25] [16]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Idarubicin and Osimertinib. Lung cancer [2C25] [34]
Capmatinib DMYCXKL Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [19]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Idarubicin and Selpercatinib. Lung cancer [2C25] [17]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Idarubicin and Lumefantrine. Malaria [1F40-1F45] [35]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Idarubicin and Halofantrine. Malaria [1F40-1F45] [36]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Idarubicin and Hydroxychloroquine. Malaria [1F40-1F45] [37]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [17]
Ponatinib DMYGJQO Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Ponatinib. Mature B-cell lymphoma [2A85] [19]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Idarubicin and Vemurafenib. Melanoma [2C30] [16]
LGX818 DMNQXV8 Moderate Increased risk of prolong QT interval by the combination of Idarubicin and LGX818. Melanoma [2C30] [38]
Lasmiditan DMXLVDT Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Lasmiditan. Migraine [8A80] [39]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Idarubicin and Panobinostat. Multiple myeloma [2A83] [40]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Idarubicin and Tecfidera. Multiple sclerosis [8A40] [41]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Idarubicin and Siponimod. Multiple sclerosis [8A40] [35]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Idarubicin and Fingolimod. Multiple sclerosis [8A40] [42]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Idarubicin and Ocrelizumab. Multiple sclerosis [8A40] [43]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Idarubicin and Ozanimod. Multiple sclerosis [8A40] [17]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Romidepsin. Mycosis fungoides [2B01] [16]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Idarubicin and Nilotinib. Myeloproliferative neoplasm [2A20] [16]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Dasatinib. Myeloproliferative neoplasm [2A20] [44]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Idarubicin and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [45]
Rolapitant DM8XP26 Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [46]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Entrectinib. Non-small cell lung cancer [2C25] [35]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Idarubicin and Levomethadyl Acetate. Opioid use disorder [6C43] [17]
Lofexidine DM1WXA6 Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Lofexidine. Opioid use disorder [6C43] [16]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Rucaparib. Ovarian cancer [2C73] [16]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Triclabendazole. Parasitic worm infestation [1F90] [16]
Istradefylline DM20VSK Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Istradefylline. Parkinsonism [8A00] [19]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Pimavanserin. Parkinsonism [8A00] [47]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Idarubicin and Macimorelin. Pituitary gland disorder [5A60-5A61] [48]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Idarubicin and Lefamulin. Pneumonia [CA40] [49]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Degarelix. Prostate cancer [2C82] [17]
ABIRATERONE DM8V75C Moderate Decreased clearance of Idarubicin due to the transporter inhibition by ABIRATERONE. Prostate cancer [2C82] [19]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Enzalutamide. Prostate cancer [2C82] [17]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Relugolix. Prostate cancer [2C82] [17]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Levomepromazine. Psychotic disorder [6A20-6A25] [16]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Idarubicin and Canakinumab. Rheumatoid arthritis [FA20] [50]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Idarubicin and Rilonacept. Rheumatoid arthritis [FA20] [50]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Idarubicin and Golimumab. Rheumatoid arthritis [FA20] [51]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Quetiapine. Schizophrenia [6A20] [16]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Aripiprazole. Schizophrenia [6A20] [35]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Idarubicin and Iloperidone. Schizophrenia [6A20] [16]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Paliperidone. Schizophrenia [6A20] [16]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Idarubicin and Amisulpride. Schizophrenia [6A20] [52]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Asenapine. Schizophrenia [6A20] [16]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Idarubicin when combined with Anthrax vaccine. Sepsis [1G40-1G41] [53]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Idarubicin and LEE011. Solid tumour/cancer [2A00-2F9Z] [16]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Idarubicin and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [16]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [17]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Pitolisant. Somnolence [MG42] [16]
Telavancin DM58VQX Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [16]
Fostamatinib DM6AUHV Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Fostamatinib. Thrombocytopenia [3B64] [54]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Lenvatinib. Thyroid cancer [2D10] [16]
Elagolix DMB2C0E Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Elagolix. Uterine fibroid [2E86] [19]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [55]
Propafenone DMPIBJK Moderate Decreased clearance of Idarubicin due to the transporter inhibition by Propafenone. Ventricular tachyarrhythmia [BC71] [19]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Idarubicin and Flecainide. Ventricular tachyarrhythmia [BC71] [16]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Idarubicin and Valganciclovir. Virus infection [1A24-1D9Z] [35]
⏷ Show the Full List of 110 DDI Information of This Drug

References

1 Idarubicin FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7083).
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
8 Amonafide L-malate is not a substrate for multidrug resistance proteins in secondary acute myeloid leukemia. Leukemia. 2008 Nov;22(11):2110-5.
9 In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin. Hematology. 2004 Jun;9(3):217-21.
10 Quantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptor. Sci Rep. 2014 Sep 26;4:6437. doi: 10.1038/srep06437.
11 The induction of apoptosis by daunorubicin and idarubicin in human trisomic and diabetic fibroblasts. Cell Mol Biol Lett. 2008;13(2):182-94. doi: 10.2478/s11658-007-0045-7. Epub 2008 Apr 10.
12 A Quantitative Approach to Screen for Nephrotoxic Compounds In Vitro. J Am Soc Nephrol. 2016 Apr;27(4):1015-28. doi: 10.1681/ASN.2015010060. Epub 2015 Aug 10.
13 The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia. Neoplasma. 2005;52(5):430-4.
14 Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
15 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
16 Canadian Pharmacists Association.
17 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
18 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
19 Multum Information Services, Inc. Expert Review Panel.
20 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
21 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
22 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
23 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
24 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
25 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
26 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
27 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
28 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
29 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
30 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
31 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
32 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
33 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
34 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
35 Cerner Multum, Inc. "Australian Product Information.".
36 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
37 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
38 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
39 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
40 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
41 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
42 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
43 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
44 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
45 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
46 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
47 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
48 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
49 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
50 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
51 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
52 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
53 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
54 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.
55 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]